BRD2 and cancer: However, five of these peptides did not pass the initial classifications in our pipeline (≥10 FC in cancer compared with NAT and ≤2 RPHM in NAT), and the other was found to be expressed more than 8.55 RPHM in mTECs (supplemental Table S2).